Please assess the completion status of the following clinical trial:

Trial Title: A Study to Compare the Use of Ferric Carboxymaltose With Placebo in Patients With Chronic Heart Failure and Iron Deficiency

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Iron deficient subjects with stable chronic heart failure (CHF) (NYHA II-III) on optimal background therapy for CHF~* Reduced left ventricular ejection fraction~* Capable of completing 6 minute walk test~* At least 18 years of age and with written informed consent prior to any study specific procedures~Exclusion Criteria:~* Erythropoietin stimulating agent (ESA) use, IV iron therapy and/or blood transfusion in previous 6 weeks prior to randomisation~* Exercise training program(s) in the 3 months prior to screening or planned in the next 6 months~* Chronic liver disease and/or elevated liver enzymes~* Vitamin B12 and/or serum folate deficiency~* Subject is not using adequate contraceptive precautions during the study~* Body weight ≤ 35 kg~* No other significant cardiac or general disorders that would compromise the ability to give informed consent and/or comply with study procedures

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ferinject (ferric carboxymaltose) (Type: EXPERIMENTAL): None
- Placebo (saline) (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).